Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients.

Neeraj BadjatiaNidhi GuptaStephanie SanchezJoseph HaymoreHemantkumar TripathiRushil ShahCasey HannanHarikrishna Tandri

Published in: Neurocritical care (2021)

Inducing normothermia with a novel transnasal TMD appears to be safe, feasible and not associated with significant shivering. A multicenter trial testing the ability of the CoolStat to maintain normothermia for 24 h is currently underway.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
study protocol
cross sectional